Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 132

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Blood (2025) 146 (Supplement 1): 89.

https://doi.org/10.1182/blood-2025-89

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Mariela Sivina, Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip Thompson, Hagop Kantarjian, Michael Keating, Jan A. Burger

Blood (2021) 138 (24): 2589–2592.

https://doi.org/10.1182/blood.2021012315

Published: 2021

Includes: Supplemental data

Journal Articles

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

Blood (2019) 134 (8): 688–698.

https://doi.org/10.1182/blood.2019000490

Published: 2019

Includes: Supplemental data

Journal Articles

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps

Blood (2018) 131 (25): 2745–2760.

https://doi.org/10.1182/blood-2017-09-806398

Published: 2018

Journal Articles

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

Blood (2018) 131 (16): 1820–1832.

https://doi.org/10.1182/blood-2017-11-817296

Published: 2018

Includes: Supplemental data

Journal Articles

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Paolo Strati, MD, Philip A Thompson, MBBS, Michael Keating, MBBS, Christina Hinojosa, Diana Rodriguez, Xuemei Wang, MS, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, William G. Wierda, MD PhD, Hagop M. Kantarjian, MD, Susan Obrien, MD BA, Alessandra Ferrajoli, MD

Blood (2016) 128 (22): 4389.

https://doi.org/10.1182/blood.V128.22.4389.4389

Published: 2016

Journal Articles

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Preetesh Jain, MBBS, MD DM, PhD, Philip A Thompson, MBBS, Michael Keating, MBBS, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Hagop M. Kantarjian, MD, Jan Burger, MD PhD, Susan M. O'Brien, MD, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4390.

https://doi.org/10.1182/blood.V128.22.4390.4390

Published: 2016

Journal Articles

Routine Clinical Testing for Actionable Mutations in CLL Using Endcll Assay V1: The Initial MD Anderson Experience

Keyur P. Patel, MD PhD, Rajesh Singh, PhD, Mark Routbort, MD PhD, C. Cameron Yin, MD PhD, Rashmi Kanagal Shamanna, PhD, Nitin Jain, MD, Xinyan Lu, MD, Sherry Pierce, BSN, BA, Michael Keating, MBBS, Hagop M. Kantarjian, MD, L. Jeffrey Medeiros, MD, Raja Luthra, PhD, William G. Wierda, MD PhD

Blood (2016) 128 (22): 3196.

https://doi.org/10.1182/blood.V128.22.3196.3196

Published: 2016

Journal Articles

The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study

Philip A Thompson, MBBS, Vincent Levy, MD PhD, Constantine S. Tam, MBBS, Chadi al Nawakil, MD, Francois Xavier Goudot, MD, Anne Quinquenel, MD, Loic Ysebaert, MD PhD, Anne-Sophie Michallet, MD, Marie Sarah Dilhuydy, MD, Eric W Van Den Neste, MD PhD, Jehan Dupuis, MD, Michael Keating, MBBS, Christophe Meune, MD PhD, Florence Cymbalista, MD PhD

Blood (2016) 128 (22): 3242.

https://doi.org/10.1182/blood.V128.22.3242.3242

Published: 2016

Journal Articles

Early Achievement of MRD-Negativity in IGHV-M utated ( IGHV-M ) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse

Philip A Thompson, MBBS, Paolo Strati, MD, Michael Keating, MBBS, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Jan A Burger, MD PhD, Jeffrey L. Jorgensen, MD PhD, Stefan Faderl, MD, Zeev Estrov, MD, Nitin Jain, MD, Tapan Kadia, MD, Gautam Borthakur, MBBS, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD

Blood (2016) 128 (22): 232.

https://doi.org/10.1182/blood.V128.22.232.232

Published: 2016

Journal Articles

Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells

Uri Rozovski, MD, David M. Harris, Ping LI, PhD, Zhiming Liu, Preetesh Jain, MBBS, MDDM, PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Susan M. O'Brien, MD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, William G. Wierda, MD PhD, Michael Keating, MBBS, Zeev Estrov, MD

Blood (2016) 128 (22): 4374.

https://doi.org/10.1182/blood.V128.22.4374.4374

Published: 2016

Journal Articles

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2016) 128 (22): 2012.

https://doi.org/10.1182/blood.V128.22.2012.2012

Published: 2016

Journal Articles

Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes

Ahmad Alhuraiji, MD MRCP, Lorenzo Falchi, MD, Michael Keating, MBBS, Zeev Estrov, MD, Paolo Strati, MD, William Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Alessandra Ferrajoli, MD

Blood (2016) 128 (22): 5573.

https://doi.org/10.1182/blood.V128.22.5573.5573

Published: 2016

Journal Articles

Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience

Etsuko Aoki, MDPhD, Preetesh Jain, MBBS, MDDM, PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Elias Jabbour, MD, Sherry Pierce, BSN, BA, Chitra Hosing, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD

Blood (2016) 128 (22): 2997.

https://doi.org/10.1182/blood.V128.22.2997.2997

Published: 2016

Journal Articles

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Francesco Paolo Tambaro, MD PhD, Clelia Criscuolo, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Philip A Thompson, MBBS, Jan Burger, MD PhD, Zeev Estrov, MD, Mimmo Ripaldi, MD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael Keating, MBBS, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4351.

https://doi.org/10.1182/blood.V128.22.4351.4351

Published: 2016

Journal Articles

Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo

Uri Rozovski, MD, David M. Harris, Ping LI, PhD, Zhiming Liu, Preetesh Jain, MBBS, MDDM,PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Susan M. O'Brien, MD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, William G. Wierda, MD PhD, Michael Keating, MBBS, Zeev Estrov, MD

Blood (2016) 128 (22): 4348.

https://doi.org/10.1182/blood.V128.22.4348.4348

Published: 2016

Journal Articles

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

Blood (2016) 128 (22): 59.

https://doi.org/10.1182/blood.V128.22.59.59

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Routine Clinical Testing for Actionable Mutations in CLL Using Endcll Assay V1: The Initial MD Anderson Experience

The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study

Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes

Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only